Alarming Surge in "Turbo Cancers": Italian Study Links COVID mRNA Vaccines to Increased Cancer Risks

Originally published: 2025-09-07

A recent peer-reviewed study from Italy has sent ripples through the medical community, revealing a potential association between COVID-19 mRNA vaccines and heightened risks of certain cancers. Published in the EXCLI Journal, this population-wide cohort analysis tracked nearly 300,000 individuals over 30 months, exposing troubling trends in cancer hospitalizations among the vaccinated. While the study emphasizes its preliminary nature and calls for further investigation, the findings demand attention, particularly regarding the spike protein’s role in disrupting immune and inflammatory processes.

The Study at a Glance: A Population-Wide Wake-Up Call

Led by Cecilia Acuti Martellucci and colleagues from the University of Bologna and local health authorities, the research utilized official National Health System data from Pescara province, Italy. It followed 296,015 residents aged 11 and older from June 2021 to December 2023, categorizing them by vaccination status: unvaccinated (16.6%), those with at least one dose (83.3%), and those with at least three doses (62.2%). Vaccines included mRNA types like Pfizer-BioNTech and Moderna, as well as others.

The primary focus was on all-cause mortality and first-time cancer hospitalizations (excluding non-melanoma skin cancers). After adjusting for variables like age, sex, comorbidities, and prior COVID-19 infection, the results painted a stark picture for cancer risks.

“Compared with the unvaccinated, those receiving ≥1 dose showed... a slightly higher likelihood of hospitalization for cancer (HR: 1.23; 95% CI: 1.11–1.37).”

Overall, 3,134 individuals were hospitalized for cancer during the follow-up period, representing 1.10% of the sample. The rate was 0.85% among the unvaccinated but climbed to 1.15% for those with at least one dose. This elevated risk was more pronounced in those without prior SARS-CoV-2 infection (HR: 1.31 for ≥1 dose) and diminished or reversed with longer lag times between vaccination and diagnosis, suggesting possible short-term effects or biases.

Sharp Increases in Specific Cancers: Breast, Bladder, and Beyond

The study didn’t just stop at overall cancer rates. It broke down the risks by site, revealing significant spikes in several aggressive cancers often dubbed “turbo cancers” in public discourse for their rapid progression.

Multivariate analyses confirmed higher hazard ratios for:

Breast cancer: HR 1.54 (95% CI: 1.10–2.16) for ≥1 dose, HR 1.36 (95% CI: 1.08–1.72) for ≥3 doses
Bladder cancer: HR 1.62 (95% CI: 1.07–2.45) for ≥1 dose, HR 1.43 (95% CI: 1.08–1.88) for ≥3 doses
Colorectal cancer: HR 1.35 (95% CI: 1.01–1.80) for ≥1 dose
Hematological cancers: Elevated at univariate levels, though multivariate HR was 1.27 (not statistically significant)

These associations held for some cancers even with a 365-day lag, particularly breast and bladder, while others like lung and prostate showed no increase or even slight reductions with booster doses.

“At univariate analyses, vaccinated subjects showed higher rates for colon-rectum, breast, bladder, and all hematological cancers.”

This data aligns with anecdotal reports of rapid-onset cancers post-vaccination, fueling concerns about mRNA technology’s long-term impacts.

Diving Deep: Spike Protein’s Role in Inflammation and Immune Dysfunction

A core revelation of the study lies in its discussion of potential pathophysiological mechanisms. The authors reference several reviews to outline how the vaccine-induced spike protein, mimicking that of SARS-CoV-2, could promote cancer through inflammatory and immune-disrupting pathways.

The spike protein, produced by host cells following mRNA vaccination, is implicated in a multi-hit oncogenic process. Key mechanisms include:

Pro-Inflammatory Effects – The spike protein triggers systemic inflammation, potentially fostering a tumorigenic environment. It affects mucosal surfaces like the gut, leading to chronic inflammation that could accelerate cancer growth.
Immune Suppression – Reduced Type 1 interferon activity impairs the body’s antiviral and anti-tumor defenses, allowing abnormal cells to proliferate unchecked.
Lymphopenia and Altered MicroRNA – Vaccination may cause temporary lymphopenia (low lymphocyte counts) and disrupt cellular microRNA translation, both of which can hinder immune surveillance against emerging cancers.
Lipid Nanoparticle (LNP) Contributions – The LNPs used to deliver mRNA distribute widely, exerting pro-inflammatory effects in organs and potentially exacerbating spike-related damage.

“Vaccination may promote or expedite the oncogenic multi-hit process through... pro-inflammatory and tumorigenic effects triggered by the vaccine mRNA and vaccine-induced Spike protein... reduced Interferon type 1 activity... and lymphopenia.”

These processes echo “spikeopathy,” a term for spike protein pathogenicity highlighted in related literature, where the protein acts like a toxin, disrupting homeostasis and promoting diseases like thrombosis and autoimmunity, which could indirectly fuel cancer.

Broader Implications: What This Means for Public Health

While the study found vaccinated individuals had lower all-cause mortality (HR 0.42 for ≥1 dose), the cancer signals raise questions about trade-offs, especially for younger or low-risk groups. The association was strongest in those without prior infection, hinting that natural immunity might mitigate some risks.

However, limitations abound: The use of hospitalizations as a proxy for incidence may miss outpatient cases, and unmeasured confounders like smoking or healthcare access could skew results. The “healthy vaccinee bias” might also play a role, as healthier people were more likely to get vaccinated.

“Given that it was not possible to quantify the potential impact of the healthy vaccinee bias and unmeasured confounders, these findings are inevitably preliminary.”

This calls for urgent, large-scale studies using cancer registries to confirm or refute these links. In the meantime, it underscores the need for personalized vaccination strategies and vigilance for post-vaccine symptoms.

Final Thoughts: Time to Rethink Vaccine Safety?

This Italian study isn’t definitive proof of causation, but it shatters the complacency surrounding mRNA vaccines. By spotlighting spike protein’s inflammatory and immune-modulating effects, it opens the door to understanding “turbo cancers” and other adverse events. As we navigate post-pandemic recovery, transparency and rigorous science must guide us, not narratives. If these findings hold, they could reshape vaccine development and public trust forever